Cui L - Search Results

1

Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.

Mehdipour P, Rajasekhar M, Dini S, Zaloumis S, Abreha T, Adam I, Awab GR, Baird JK, Brasil LW, Chu CS, Cui L, Daher A, do Socorro M Gomes M, Gonzalez-Ceron L, Hwang J, Karunajeewa H, Lacerda MVG, Ladeia-Andrade S, Leslie T, Ley B, Lidia K, Llanos-Cuentas A, Longley RJ, Monteiro WM, Pereira DB, Rijal KR, Saravu K, Sutanto I, Taylor WRJ, Thanh PV, Thriemer K, Vieira JLF, White NJ, Zuluaga-Idarraga LM, Guerin PJ, Price RN, Simpson JA, Commons RJ; WWARN Vivax Adherence Study Group. Mehdipour P, et al. Among authors: cui l. Malar J. 2023 Oct 10;22(1):306. doi: 10.1186/s12936-023-04725-w. Malar J. 2023. PMID: 37817240 Free PMC article.

2

Molecular markers of dihydroartemisinin-piperaquine resistance in northwestern Thailand.

Win KN, Manopwisedjaroen K, Phumchuea K, Suansomjit C, Chotivanich K, Lawpoolsri S, Cui L, Sattabongkot J, Nguitragool W. Win KN, et al. Among authors: cui l. Malar J. 2022 Nov 27;21(1):352. doi: 10.1186/s12936-022-04382-5. Malar J. 2022. PMID: 36437462 Free PMC article.

3

Evaluation of transmission-blocking potential of Pv22 using clinical Plasmodium vivax infections and transgenic Plasmodium berghei.

Bai J, Liu F, Yang F, Zhao Y, Jia X, Thongpoon S, Roobsoog W, Sattabongkot J, Zheng L, Cui Z, Zheng W, Cui L, Cao Y. Bai J, et al. Among authors: cui z, cui l. Vaccine. 2023 Jan 9;41(2):555-563. doi: 10.1016/j.vaccine.2022.11.058. Epub 2022 Dec 8. Vaccine. 2023. PMID: 36503858 Free PMC article.

4

Community acceptability, participation, and adherence to mass drug administration with primaquine for Plasmodium vivax elimination in Southern Thailand: a mixed methods approach.

Saita S, Roobsoong W, Khammaneechan P, Sukchan P, Lawpoolsri S, Sattabongkot J, Cui L, Okanurak K, Phuanukoonnon S, Parker DM. Saita S, et al. Among authors: cui l. Malar J. 2023 Jan 13;22(1):17. doi: 10.1186/s12936-023-04443-3. Malar J. 2023. PMID: 36635642 Free PMC article.

5

Correction: G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination.

Han KT, Han ZY, Aye KH, Wai KT, Thi A, Cui L, Sattabongkot J. Han KT, et al. Among authors: cui l. Trop Med Health. 2023 Feb 6;51(1):8. doi: 10.1186/s41182-023-00498-9. Trop Med Health. 2023. PMID: 36740714 Free PMC article. No abstract available.

6

Factors hindering coverage of targeted mass treatment with primaquine in a malarious township of northern Myanmar in 2019-2020.

Aung PL, Soe MT, Soe TN, Oo TL, Win KM, Cui L, Kyaw MP, Sattabongkot J, Okanurak K, Parker DM. Aung PL, et al. Among authors: cui l. Sci Rep. 2023 Apr 12;13(1):5963. doi: 10.1038/s41598-023-32371-4. Sci Rep. 2023. PMID: 37045879 Free PMC article.

7

Prevalence of G6PD deficiency and diagnostic accuracy of a G6PD point-of-care test among a population at risk of malaria in Myanmar.

Aung TH, Suansomjit C, Tun ZM, Hlaing TM, Kaewkungwal J, Cui L, Sattabongkot J, Roobsoong W. Aung TH, et al. Among authors: cui l. Malar J. 2023 May 1;22(1):143. doi: 10.1186/s12936-023-04559-6. Malar J. 2023. PMID: 37127600 Free PMC article.

8

Genetic diversity and molecular evolution of Plasmodium vivax Duffy Binding Protein and Merozoite Surface Protein-1 in northwestern Thailand.

Tapaopong P, da Silva G, Chainarin S, Suansomjit C, Manopwisedjaroen K, Cui L, Koepfli C, Sattabongkot J, Nguitragool W. Tapaopong P, et al. Among authors: cui l. Infect Genet Evol. 2023 Sep;113:105467. doi: 10.1016/j.meegid.2023.105467. Epub 2023 Jun 15. Infect Genet Evol. 2023. PMID: 37330027 Free PMC article.

9

Interventions for promoting patients' adherence to 14-day primaquine treatment in a highly malaria-endemic township in Myanmar: A qualitative study among key stakeholders.

Win KM, Aung PL, Ring Z, Linn NYY, Kyaw MP, Nguitragool W, Cui L, Sattabongkot J, Lawpoolsri S. Win KM, et al. Among authors: cui l. Res Sq [Preprint]. 2023 Sep 6:rs.3.rs-3312278. doi: 10.21203/rs.3.rs-3312278/v1. Res Sq. 2023. Update in: Malar J. 2023 Oct 9;22(1):302. doi: 10.1186/s12936-023-04743-8. PMID: 37720045 Free PMC article. Updated. Preprint.

10

Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis.

Commons RJ, Rajasekhar M, Edler P, Abreha T, Awab GR, Baird JK, Barber BE, Chu CS, Cui L, Daher A, Gonzalez-Ceron L, Grigg MJ, Hwang J, Karunajeewa H, Lacerda MVG, Ladeia-Andrade S, Lidia K, Llanos-Cuentas A, Longley RJ, Pereira DB, Pasaribu AP, Pukrittayakamee S, Rijal KR, Sutanto I, Taylor WRJ, Thanh PV, Thriemer K, Vieira JLF, Watson JA, Zuluaga-Idarraga LM, White NJ, Guerin PJ, Simpson JA, Price RN; WorldWide Antimalarial Resistance Network (WWARN) Vivax Primaquine Dosing Efficacy, Tolerability and Safety Study Group. Commons RJ, et al. Among authors: cui l. Lancet Infect Dis. 2024 Feb;24(2):172-183. doi: 10.1016/S1473-3099(23)00430-9. Epub 2023 Sep 22. Lancet Infect Dis. 2024. PMID: 37748496 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,857 results

Search Page

Filters